When metabolic comorbidities were analyzed (hypertension, T2DM, and DLP), their improvement was associated with increased baseline levels of the inflammasome activation component IL18R (Figure 6A; CASP4 and TGFB tended to be also overexpressed in these patients). This evidence concerns the gene IL18R1 and Hypertension.